Objective-Clinical evidence has linked vascular calcification in advanced atherosclerotic plaques with overt cardiovascular disease and mortality. Bone resorbing monocyte-derived osteoclast-like cells are sparse in these plaques, indicating that their differentiation capability could be suppressed. Here, we seek to characterize the process of osteoclastogenesis by identifying novel regulators and pathways, with the aim of exploring possible strategies to reduce calcification. Approach and Results-We used a quantitative mass spectrometry strategy, tandem mass tagging, to quantify changes in the proteome of osteoclast-like cells differentiated from RAW264.7 cells in response to, receptor activator of nuclear factor κ-B ligand induction, a common in vitro model for osteogenesis. More than 4000 proteins were quantified, of which 138 were identified as novel osteoclast-related proteins. We selected 5 proteins for subsequent analysis (cystathionine γ-lyase [Cth/CSE], EGF-like repeat and discoidin I-like domain-containing protein 3, integrin α FG-GAP repeat containing 3, adseverin, and serpinb6b) and show that gene expression levels are also increased. Further analysis of the CSE transcript profile reveals an early onset of an mRNA increase. Silencing of CSE by siRNA and dl-propargylglycine, a CSE inhibitor, attenuated receptor activator of nuclear factor κ-B ligand-induced tartrate-resistant acid phosphatase type 5 activity and pit formation, suggesting that CSE is a potent inducer of calcium resorption. Moreover, knockdown of CSE suppressed expression of osteoclast differentiation markers.
W estern societies face a growing burden of cardiovascular calcification, a disease of disordered mineral metabolism. 1, 2 The interaction between prevalent epidemiological factors, such as age, hypercholesterolemia, and renal insufficiency, accelerates arterial and aortic valve calcification. Cardiovascular calcification causes devastating complications, including acute coronary events, because of plaque rupture and aortic valve stenosis. [3] [4] [5] [6] However, no medical therapies are currently available to retard or to reduce cardiovascular calcification, 7 which has driven the exploration of underlying mechanisms.
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Emerging evidence suggests that vascular calcification is an active process, rather than mere tissue degeneration, akin to that of bone formation that involves 2 major cell types: osteoblasts and osteoclasts. In the vascular wall, osteoblastlike cells, differentiated from vascular smooth muscle cells (SMCs), can generate calcium deposition, whereas osteoclastlike cells, differentiated from hematopoietic precursors of the mononuclear phagocyte lineage, might dissolve mineralized deposition. 8 Histological studies have shown that calcified atherosclerotic lesions from humans and mice accumulate osteoblast-like cells, whereas a relatively fewer number of osteoclast-like cells are found. 9 Our hypothesis posits that molecular regulators cause osteoclast or osteoblast dominance in atherosclerotic regions. To understand the mechanisms behind osteoclastogenesis, we conducted a proteomic analysis using receptor activator of nuclear factor κ-B ligand (RANKL)-induced osteoclast differentiation of the murine macrophage-like cell line RAW264.7, a commonly used model of osteoclastogenesis. Cellular proteins were analyzed by tandem mass tagging (TMT)-based quantitative mass spectrometry analysis. 10 A selected set of proteins with increased activity and expression in differentiated RAW264.7 cells was studied further, leading to a novel osteoclast regulator, cystathionine γ-lyase (CSE). Our validation studies demonstrate that CSE accelerates monocyte-derived osteoclast-like differentiation and has a potent calcium resorption function. CSE was also shown by others 11 to suppress osteoblast differentiation. Taken together, CSE may serve as a molecular switch regulating osteoclast-osteoblast balance in vascular wall.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

TMT Strategy Applied to RANKL-Induced Osteoclastogenesis
To correlate changes in the proteome with RANKL-induced osteoclastogenesis, we used the isobaric TMT approach (Figure 1 ). 9 Treatment with RANKL induced the formation of TRAP stain positive multinucleated cells by day 3, a feature typical of osteoclasts ( Figure 1A ). Differentiation of RAW264.7 cells into osteoclast-like cells was also confirmed by TRAP activity assay in the cell culture supernatant ( Figure 1B ). Individual populations of tryptic peptides generated from 3 replicates of control and RANKL-stimulated RAW264.7 cells were covalently modified to 1 of 6 isobaric chemical reagents labeled 126 through 131 ( Figure 1C ). As a consequence, all 6 TMT-modified peptide samples can be combined for subsequent fractionation and liquid chromatography/mass spectrometry analysis. In the first MS scan, the 6 peptide populations represent themselves as a single MS signal ( Figure 1D ); however, during tandem MS (MS2), fragmentation of the TMT-tagged peptides generates ions not only for peptide sequencing but also ions in the lower m/z range that contains the reporter mass tags (126-131), whose respective intensities vary according to their respective peptide/protein relative abundances in the original samples ( Figure 1D and 1E).
Evaluation of the Global Proteomics Data and Confirmation of Known Osteoclast Markers
We performed two 6-plex TMT experiments, each investigating 3 biological replicates of control (macrophage) versus RANKL-induced osteoclast cells, for a total of 6 biological replicates. The combined TMT experiments generated a total of 59 833 TMT-labeled peptides and 5586 (3729 overlapping) quantified proteins with ≥2 unique peptides ( Figure 2A ). When the combined data sets were filtered to include proteins whose summed unique peptides were ≥2 (where each TMT experiment provided a single unique peptide), we increased the final overlapping protein number to 4244 proteins for the final analysis ( Figure 2B ). Overall, the 2 TMT experiments produced consistent quantification of protein ratios ( Figure 2C ). MS2 spectrum of a known osteoclast-associated marker, TRAP/Acp5 is shown in Figure 2D . In addition to the fragment ion spectra required for peptide identification, the TMT reporter ion spectra provide the relative changes in peptide abundance between the 2 cell states. As expected for Acp5, for example, the TMT spectrum displays a marked increase in its associated peptide abundance in all 3 osteoclast states with respect to those in the macrophage states ( Figure 2D ). This increase in abundance is in contrast to the TMT reporter ion profile for proteasome subunit β type-3 whose reporter ion intensities remain constant across all 6 samples ( Figure 2E ). The TMT spectra from representative peptides of EGF-like repeat and discoidin I-like domain-containing protein 3 (Edil3; Figure 2F ) and Cth/CSE ( Figure 2G ) reveal that these proteins increased as a function of osteoclastogenesis.
Proteins determined to increase (78 proteins) or to decrease (127 proteins) after Bonferroni correction significantly (threshold set at α=0.05) are indicated in the red boxes ( Figure 2B ). The Bonferroni correction adjusts the significance cut-off (α=0.05) as a function of sample number (n=4244) and is considered a strict or conservative estimation of significance. Most known osteoclast and macrophage-specific markers are significant outliers after the Bonferroni correction; however, alternative and more relaxed cut-off methods, such as the standard ratio threshold cut-off at P=0.05 or the false discovery rate calculated cut-off q=0.05, ensure that all marker proteins are considered as significantly regulated (not shown).
Known osteoclast markers cathepsin K, osteoclast-associated receptor, and TRAP/Acp5 increase in abundance as expected ( Figure 2B ), whereas known macrophage markers, lysozyme C-2 and C-1 and CD14, decrease in abundance as expected ( Figure 2B ). Table 1 displays a list of previously studied osteoclast-related proteins and their relative changes in abundance.
Identification of Novel Osteoclast-Specific Proteins
Once the expression profiles of known osteoclast-associated makers were verified, we screened the data set for putative novel osteoclast proteins (ie, proteins whose expression increased as a consequence of RANKL-induced osteoclastogenesis; Figure 2B ). Using a 1.5-fold cut-off (P=0.01), 440 proteins remained, including a number of known markers (Table 1 ). We then cross-referenced the literature to reduce our list further to proteins not previously associated with osteoclastogenesis, resulting in a final list of 138 candidates ( Table I in the online-only Data Supplement). Selected proteins are listed in Table 2 , including Edil3, integrin α FG-GAP repeat containing 3 (Itfg3), serpinb6b, adseverin, and Cth/CSE. These novel candidate osteoclast-associated proteins represent a variety of biological processes ( Table 2 ; Table II in the online-only Data Supplement) for avenues for potential follow-up.
mRNA and Protein Levels for CSE, Edil3, Itfg3, Adseverin, and Serpinb6b Increased in Differentiated Osteoclast-Like Cells
To determine whether our candidates increase in expression in both RAW264.7 cells and in mouse bone marrowderived osteoclasts, we first performed Western blot analysis. Consistent with the proteomics data ( Figure 2 ), Western blots in Figure 3A show an increase in Cth/CSE, adseverin, and cathepsin K for RANKL-induced osteoclasts. Western blot analysis for Edil3 demonstrated no difference in signal in the 2 conditions (not shown) and detected no signal for Itfg3 and Serpinb6b. Discrepancies between quantitative mass spectrometry results and Western blot analysis are not uncommon and can usually be resolved when investigated further. 12 The mRNA levels for all 5 candidate proteins (CSE, Edil3, Itfg3, adseverin, and serpinb6b) and controls (cathepsin K, TRAP, and matrix metalloproteinase 9 [MMP9]) significantly increased in differentiated RAW264.7 cells ( Figure 3B ). Time course analysis of differentiating RAW264.7 cells showed that CSE mRNA levels peak between days 1 and 2 of RANKL induction and decrease by day 3 ( Figure I in the online-only Data Supplement). These data indicate that while CSE protein levels are higher in the differentiated state (day 3), peak activity is likely to have occurred earlier. However, Itfg3, adseverin, and serpinb6b showed steady increases in mRNA levels throughout differentiation, similar to controls (cathepsin K, TRAP, and MMP9), whereas Edil3 mRNA levels peak by day 1 and remained stable until day 3.
In mouse bone marrow cells stimulated with RANKL for 7 days, increased protein levels (CSE, adseverin, and cathepsin K) were detected by Western blot ( Figure 3A ). An increase of mRNA levels of the candidate proteins was also observed, with the exception of CSE ( Figure 3C ). However, a time course analysis revealed an increase in CSE mRNA levels at day 3 of RANKL stimulation, followed by a steady decrease of mRNA until day 7 ( Figure II in the online-only Data Supplement). All but one gene (Itfg3) displays the most drastic increase mRNA levels by day 3; the variability in the Itfg3 measurements is likely because of the relative low transcription levels ( Figure  II in the online-only Data Supplement).
This analysis highlights the importance of investigating time-dependent regulation of mRNA and protein induction to ensure that key windows of expression are not missed. Overall, the transcript profiling is consistent with the quantitative proteomics data and suggests that increases in the protein levels were a result of increased transcription and translation.
CSE Is a Regulator of Osteoclastogenesis
An immune-localization study of the expression pattern of CSE in RANKL-induced osteoclasts ( Figure 4A) shows that cytosolic expression of CSE is observed in control cells; however, expression is redistributed in differentiated osteoclasts, specifically around the nuclei and clearly contained within the F-actin boundary ring structure ( Figure 4A, arrow) , a hallmark for the osteoclast phenotype. 13 To understand whether CSE is required for osteoclastogenesis, we performed siRNA experiments targeting CSE and as a control, RANK. siRNA was transfected 24 hours before cells were stimulated with RANKL, thus preventing TMT2) . B, The normalized log ratio plot of (osteoclast/macrophage) protein abundances from TMT experiment 2. Proteins known to increase or decrease during osteoclastogenesis are indicated. The number of quantified peptides is indicated in parentheses. n=4244 and significant outliers (α < 0.05) are highlighted in the red boxes. C, A correlation plot of the TMT1 and TMT2 normalized log ratios (osteoclast/macrophage). D-G, Example of MS2 peptide spectra; a known osteoclast marker, Acp5 (TRAP; D); Psb3, a control protein whose abundance did not change as a function of osteoclastogenesis (E); and 2 novel osteoclast-associated proteins identified in this study, EGF-like repeat and discoidin I-like domain-containing protein 3 (Edil3; F) and cystathionine γ-lyase (Cth/CSE; G); The red box indicates the TMT reporter m/z range. The inset to the right of each spectrum is the expansion of the TMT reporters. Lower-case letters in the peptide sequences indicate the sites of TMT labeling. The peak corresponding to the TMT tag minus the NHS-ester (m/z 230.17) was sometimes observed (black dot). Inset, Gray dots indicate reporters from the macrophage controls and red dots indicate the reporters from osteoclasts. CSE activity early in RANKL-dependent signaling. By day 4 of culture, CSE silencing reduced osteoclast activity to a level comparable with that of RANK silencing, as determined by pit resorption (Figure 4B and 4D) and TRAP activity assays ( Figure 4E ). These data indicate that early inhibition of CSE levels is sufficient to inhibit osteoclast formation, consistent with the observation that CSE mRNA increases early after RANKL induction ( Figure I in the online-only Data Supplement). CSE activity is also inhibited by the small molecule, dl-propargylglycine. 14 RANKL-treated RAW264.7 cells Listed are known proteins and their respective gene names to be associated with either the RAW264.7 macrophage state (decreased ratio) or RANKLinduced osteoclast state (increased ratio). RANKL indicates receptor activator of nuclear factor κ-B ligand; and TRAP, tartrate-resistant acid phosphatase type 5.
Table 2. Selected Novel Osteoclast Associated Proteins and Their Respective Gene Names Identified in This Study
Protein Name
Gene Name were cultured in the presence or in the absence of 5 mmol/L dl-propargylglycine for 4 days. Pit resorption (Figure 4C and 4F) and TRAP activity ( Figure 4G ) assays demonstrate that dlpropargylglycine-dependent inhibition of CSE was also sufficient to inhibit osteoclast function.
To investigate whether CSE inhibition of osteoclast formation influences the expression patterns of the typical osteoclast markers, cathepsin K, TRAP, and MMP9, we assessed their mRNA levels on siRNA-mediated reduction of CSE ( Figure 4H ). CSE knockdown significantly reduced levels of the osteoclast markers although not to the extent of RANK siRNA ( Figure 4H ). Likewise, reduction of CSE activity by the dl-propargylglycine inhibitor reduced the mRNA levels of cathepsin K and MMP9 in RANKL-induced conditions; however, we could not confirm any significant change in the level of TRAP mRNA ( Figure 4I ).
We then investigated whether the dl-propargylglycinedependent inhibition modified the levels of macrophage marker genes, CD14, Lyz1, Lyz2, and F4/80. Indeed, a reduction in RANKL-induced suppression was observed for all macrophage markers although CD14 was not significant ( Figure III in the online-only Data Supplement). This result suggests that CSE is an important regulator of osteoclastogenesis and not just an outcome of the process.
Our results indicate that CSE may regulate osteoclast formation through its product H 2 S. The addition of a H 2 S donor (GYY4137) significantly increased the number of TRAP positive osteoclasts, marked by their multinucleate phenotype, as judged by TRAP and pit resorption assays ( Figure 5A-5C ). Moreover, GYY4137 was able to rescue dl-propargylglycinedependent inhibition of osteoclastogenesis ( Figure 5D ), indicating that CSE activity involves H 2 S-dependent mechanisms.
Plaque Macrophages and Osteoclast-Like Cells Expressed CSE
To examine the expression of CSE in atherosclerotic plaques, we performed immunohistochemistry in the aortas of apoE-deficient mice and wild-type controls. We found strong CSE expression in intimal and medial SMCs. In addition, CSE coexpressed with the macrophage marker CD68 and the osteoclast marker osteoclast-associated receptor (OSCAR) ( Figure 6 , arrows showing coexpressed cells). CSE expression was low in the aortas of wild-type mice.
Discussion
A major breakthrough in osteoclast biology occurred with the characterization of RANKL, its cell surface receptor (RANK), and its decoy receptor osteoprotegerin. 15 Evidence suggests that monocytes/macrophages treated with RANKL differentiate into mature osteoclasts. 16, 17 Mice lacking RANKL or RANK also lack functional osteoclasts, indicating that RANKL signaling is necessary and sufficient for osteoclast survival and function. In our study, we turned to the RAW264.7 cell stimulated with RANKL as a common model for osteoclastogenesis. 18 Unlike previous proteomics studies, which focused on either secreted 19 or membrane proteins, 20 we have sequenced deep into the RAW264.7 proteome to reveal novel players in the transition to the osteoclast-like state. The TMT strategy, 9 in combination with the faster Orbitrap Elite platform, 21 has improved the sensitivity and scope of our study when compared with approaches such as isotope-coded affinity tag for the study of secreted proteins, 19 and peptide counting for membrane proteins. 20 As a result, we were able to monitor the relative abundances of >4000 proteins during RANKL-induced osteoclast differentiation of mouse macrophage-like cell line RAW264.7. We identified 138 candidate proteins previously unassociated with osteoclast differentiation and function. However, our particular global proteomics approach is only a snapshot of relative protein abundances between 2 distinct phenotypes; it serves as a solid starting point for subsequent in-depth follow-up of the mechanisms behind the changes in the proteome. Therefore, we investigated the time-dependent mRNA expression patterns of 5 novel osteoclast-associated proteins and found that the increase in protein abundances was because of a steady increase in transcription activity for Itfg3, adseverin, and serpinb6b for the 3-day differentiation period. However, the transcription activities for Edil3 and CSE both peaked by the first day, where mRNA levels for CSE decreased thereafter. The relative mRNA profiles of these 5 osteoclast-associated genes, although varied in their time-dependent profiles, are in accordance with their respective day 3 relative protein abundances. These observations underscore the sensitivity and accuracy of current proteomics approaches.
The selected proteins for follow-up studies, Edil3, Itfg3, serpinb6b, adseverin, and CSE, represent diverse biological functions; however, they have not been previously associated with osteoclastogenesis. It has been demonstrated that Edil3 may contribute to angiogenesis, 22 endochondral bone formation, 22 and regulate inflammation. 23, 24 Itfg3 is a single pass transmembrane protein with confirmation as a glycoprotein. 25, 26 Serpinb6b is a member of the widely studied serine protease inhibitor family, the serpins, that inhibit their enzyme targets by covalent modification, an activity that is consequential to numerous and widespread biological processes. 27 Adseverin belongs to the villin superfamily of proteins, which function in actin remodeling in response to calcium signaling. 28 Mouse adseverin was first characterized in mouse T cells and mast cells but not observed in the mouse macrophage cell line PU5.8. 29 Of the 5 novel osteoclast-associated proteins identified, CSE was of particular interest to us because of the recent findings that its product, H 2 S, suppresses vascular SMC-derived osteoblast-like cells. 30 Moreover, silencing of CSE in human aortic SMC increases osteoblastogenesis and corresponding mineralization. 31 A detailed analysis of CSE revealed that loss of function by either siRNA or drug inhibition (dl-propargylglycine) repressed osteoclast differentiation and that CSE mRNA expression could be an early marker. In addition, reduction of CSE activity also decreased the mRNA expression of canonical osteoclast markers (TRAP, cathepsin K, and MMP9). Our results suggest that CSE promotes osteoclast activity by regulating its associated enzymes and that this regulation of osteoclast formation occurs through H 2 S.
Moreover, macrophages and osteoclast-associated receptorpositive osteoclast-like cells express CSE protein in advanced murine atherosclerotic plaques. In addition, our data localized CSE to the intimal and medial SMCs of the plaques, consistent with the notion that CSE activity plays a role in osteoblastlike differentiation. 31 CSE-deficient mice, for example, display marked hypertension, 30 which may contribute to arterial wall remodeling and vascular calcification. 32 Previous and current studies have led to the promising hypothesis: early induction of CSE activity in monocytes/macrophages promotes osteoclast differentiation, while simultaneously inhibiting osteoblast programming by neighboring SMCs. CSE dysfunction may thus have a dual role in vascular calcification: a loss of osteoclast-like potential and an increase in osteoblast-like dominance. Future studies may dissect the precise mechanisms behind this putative common molecular switch for osteoclast-osteoblast balance and may offer a novel therapeutic target for vascular calcification. Clinical evidence has linked vascular calcification in advanced atherosclerotic plaques with overt cardiovascular disease and mortality. Bone resorbing osteoclasts are sparse in atherosclerotic plaques, indicating that their differentiation capability could be suppressed. In this study, we identified novel regulators of osteoclastogenesis using state-of-the-art tandem mass tagging-based quantitative mass spectrometry analysis, with the aim of exploring new strategies to reduce cardiovascular calcification. Our validation analysis revealed a new regulator of osteoclastogenesis-cystathionine γ-lyase. Here, we show that CSE accelerates monocyte-derived osteoclast differentiation and has a potent calcium resorption function, resulting in an attractive anticalcification target.
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